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Abstract
Background: Depression is a common illness with great human costs and a significant burden on the public
economy. Previous studies have indicated that collaborative care (CC) has a positive effect on symptoms when
provided to people with depression, but CC has not yet been applied in a Danish context. We therefore
developed a model for CC (the Collabri model) to treat people with depression in general practice in Denmark.
Since systematic identification of patients is an “active ingredient” in CC and some literature suggests case finding
as the best alternative to standard detection, the two detection methods are examined as part of the study. The
aim is to investigate if treatment according to the Collabri model has an effect on depression symptoms when
provided to people with depression in general practice in Denmark, and to examine if case finding is a better
method to detect depression in general practice than standard detection.
Methods/Design: The trial is a cluster-randomised, clinical superiority trial investigating the effect of treatment
according to the Collabri model for CC, compared to treatment as usual for 480 participants diagnosed with
depression in general practice in the Capital Region of Denmark. The primary outcome is depression symptoms
(Beck’s Depression Inventory (BDI-II)) after 6 months. Secondary outcomes include depression symptoms (BDI-II)
after 15 months, anxiety symptoms (Beck’s Anxiety Inventory (BAI)), level of functioning (Global Assessment of
Function (GAF)) and psychological stress (Symptom Checklist-90-Revised (SCL-90-R)). In addition, case finding
(with the recommended screening tool Major Depression Inventory (MDI)) and standard detection of depression
is examined in a cluster-randomized controlled design. Here, the primary outcome is the positive predictive value
of referral diagnosis.
Discussion: If the Collabri model is shown to be superior to treatment as usual, the study will contribute with
important knowledge on how to improve treatment of depression in general practice, with major benefit to
patients and society. If case finding is shown to be superior to standard detection, it will be recommended as the
detection method in future treatment according to the Collabri model.
Trial registration: ClinicalTrials.gov. NCT02678845. Retrospectively registered on 7 February 2016.
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Background
The treatment outcome study
Depression is a common disorder with a lifetime risk of
17–18% [1]. A Danish survey found a point prevalence
of major depression of 3.3% [2]. Based on the Danish
National Patient Register [3], including information on
all patients in Danish hospitals, the annual number of
new cases of depression admitted to a psychiatric hos-
pital is 11,000. It is estimated that 32,000 men and
59,000 women are living with depression [4]. The human
cost relating to depression is great, but the illness also
places a significant burden on the public economy. It is
estimated that the cost related to loss of production due
to depression in Denmark is approximately 0.5 billion
US dollars per annum [4]. The majority of people with
depression are treated in general practice [5], but studies
show that many patients with depression go unrecognised
or do not receive evidence-based treatment in general
practice [2, 5–7]. Some of the obstacles in the current
management and organisation of treatment of depression
that have been identified are as follows. First, there is a
lack of coordination of the management of depression, as
there is no organised, coherent treatment regime between
general practice and psychiatry. Second, there is a lack of
treatment opportunities, as most general practitioners
(GPs) are not trained to offer psychotherapy. It is esti-
mated that only around one third of GPs in Denmark are
qualified to offer cognitive behavioural therapy (CBT) [6].
However, GPs can refer patients with mild and moderate
depression to a psychologist, but part of the treatment is
paid for by the patient (with the other part being publi-
cally funded if the patient meets specific criteria). Third,
there is a shortage of independent psychiatrists and psy-
chologists trained in CBT or other evidence-based psy-
chotherapies targeting depression, delaying the specialised
treatment of patients referred from general practice [6].
National guidelines recommend that optimising depres-
sion treatment in general practice could be done through
introducing shared-care interventions, such as collabora-
tive care (CC) programmes [1]. CC stems from the recog-
nition, that patients with depression in general practice
may profit from an organisation of care corresponding to
the model introduced for other chronic diseases [7].
Health economics studies indicate that, in spite of extra
initial costs when introducing CC, the costs tend to have
recovered after 3–4 years and with substantial long-term
savings, because of reduction in sick leave and disability
pensions [8].
A Cochrane review from 2012, investigating the effects
of CC for depression, concluded that CC is associated
with significant improvements in treatment outcomes
for up to 2 years, compared with usual care [9]. There-
fore, CC represents a useful addition to clinical pathways
for adult patients with depression. The evidence is based
on research primarily conducted in the USA and England.
Until now, no studies have been conducted in Scandinavia.
The current evidence is therefore based on an organisa-
tional framework not directly applicable in a Danish con-
text, and it is not possible to know whether CC will have
the same effect in a Danish context [10]. Thus, it is neces-
sary to adjust the model to Danish conditions. The devel-
opment of a Danish model for CC (the Collabri model) for
depression was completed in 2014 in cooperation between
Danish GPs, psychiatrists and researchers. A protocol for a
cluster-randomised trial in patients with depression treated
according to the Collabri model, are presented in this art-
icle. At the same time models for CC for panic disorder,
generalized anxiety and social phobia were developed. The
trial protocol for the investigation of CC vs. treatment as
usual for these three anxiety disorders are presented in a
separate paper.
The detection of depression study
Bower et al. reports that systematic identification of pa-
tients is an “active ingredient” in CC [11], so we want to
include systematic identification in the Collabri depres-
sion study, and to use a method that can be carried out
by GPs. Studies indicate that GPs fail to diagnose about
half of patients with depression in general practice [12, 13].
There is substantial evidence that routine screening will
lead to too many false positives [12], because of the modest
prevalence of depression in primary care. However, the
US Preventive Task Force reports evidence supporting
screening for depression [14]. One factor for the opposing
conclusions is that the latter includes research where
screening is supported by subsequent treatment [15].
To sum up, screening for depression is recommended
in the USA, but not in the UK and in Denmark, where
screening is only recommended in high-risk groups [1].
Nevertheless, screening of high-risk groups is not sup-
ported by subsequent literature. A randomised controlled
trial on high-risk screening found no difference in recogni-
tion rates between the intervention group and the control
group [16]. In a prospective cohort study, as a final result of
screening, only 1% (17/1687) started treatment for major
depressive disorder [17]. Finally, in a Danish observational
study investigating high-risk screening for depression
with the Major Depression Inventory (MDI), compared
with screening with MDI on clinical suspicion (called
case-finding) and a combination of the two methods,
investigators found that screening of patients in high-
risk groups had limited effect in addition to the cheaper
and less invasive method of case-finding [18].
In the reviewed randomized controlled trials (RCTs),
screening was conducted using a variety of other tools
including the General Health Questionnaire (GHQ), Patient
Health Questionnaire (PHQ)-9, Primary Care Evaluation of
Mental Disorders (PRIME-MD), and hospital anxiety and
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depression scale (HADS), but we planned to use the MDI,
a self-assessment questionnaire that uses the diagnostic cri-
teria from International Classification of Diseases edition
10 (ICD-10) [19] and is recommended for screening and
diagnostics of depression in Denmark [1]. It has shown
good agreement with standard methods such as Schedules
for Clinical Assessment in Neuropsychiatry (SCAN), [20]
for both diagnosis and severity [1, 21]. Based on the afore-
mentioned literature and the available techniques, case-
finding is tested against standard detection of depression in
a randomised controlled design as part of the Collabri
study. Since the study on detection of depression (the de-
tection study) is incorporated with the Collabri studies and
shares much of their methods, this article presents both the
protocol (version 2) for a cluster randomised trial on treat-
ment according to the Collabri model for patients with de-
pression (the treatment outcome study) and for the study
on detection of depression (the detection of depression
study).
Methods
Aim and design
The aim of the study is to test the null hypothesis that
treatment according to the Collabri model (intervention
group) and treatment as usual (control group) has the
same effect on depression symptoms in people with de-
pression in primary care and to test the null hypothesis
that the performance of case-finding and standard detec-
tion of depression in primary care is the same. The treat-
ment outcome study is a cluster-randomised, clinical
superiority trial in 480 patients diagnosed with depres-
sion in general practice. The detection of depression
study is a cluster-randomised trial within the Collabri
study setting.
Eligibility of study participants
Cluster level
GPs with a registered provider number in the Capital
Region of Denmark, except for Bornholm, are eligible to
participate in the Collabri study of depression. The local
branch of the Organisation of General Practitioners in
Denmark and the Capital Region of Health Care have
negotiated and signed an agreement that allows the GPs
to participate in the study and sets out the terms and
conditions for it, including financial reimbursement.
Individual level
Patients are eligible for the outcome study and the de-
tection of depression study if their GP participates in the
study and the patient complies with the following inclu-
sion and exclusion criteria, assessed either by the GP at
recruitment and/or by a research assistant at a baseline
eligibility interview. Patients are eligible for the outcome
study if they are diagnosed with depression according to
the ICD-10. Patients are eligible for the detection of de-
pression study if they are referred to the study either by
their GP in the standard detection group with a depres-
sion diagnosis or by their GP in the case-finding group
with a (positive or negative) MDI score. In both studies,
patients must be 18 years of age, Danish speaking and
give her/his written informed consent to participate in
the trial on the terms described.
Patients cannot participate in the Collabri studies and
are excluded at baseline if they have a high risk of suicide,
a current psychotic condition, obsessive compulsory dis-
order (OCD), post-traumatic stress disorder (PTSD), bipo-
lar affective disorder, or alcohol or substance misuse that
prevents the person from participating in the Collabri
intervention. Patients are also excluded at baseline if they
are in current therapeutic or medical treatment for anxiety
or depression, have a pending disability pension case, or
have been treated for anxiety or depression within the last
6 months. Additionally, patients diagnosed with dementia
and patients assessed by the GP to be medically unstable,
making it impossible to adhere to treatment, cannot partici-
pate. Further, patients cannot participate if they are referred
to treatment in the secondary psychiatric caresystem not
later than at first contact with the GP after inclusion by a
research assistant is referred to treatment in the secondary
psychiatric care system. Patients in the intervention group
are excluded if they want treatment cf. the psychologist
scheme and do not want referral to the psychologist to be
preceded by treatment according to the Collabri model.
Recruitment and randomisation
Cluster level
Recruitment of GPs ran from May 2014 to July 2015.
GPs in the catchment areas of the Capital Region in
Denmark were invited to join the study through letters
with information about the project and dates for a total
of four information meetings. Additionally, the GPs were
recruited through articles in professional newsletters and
forums. Information visits and telephone calls to GPs
were made on request.
The randomisation was conducted by centralised ran-
dom computer-generated allocation sequence, carried out
externally by the Research Centre for Prevention and
Health (RCPH) at practice level, where each cluster corre-
sponds to a provider number consisting of one or more
GPs. Cluster randomisation was chosen because of the
risk of bias in the form of contamination if the randomisa-
tion was on an individual level. The GPs were randomised
to give either treatment as usual or CC according to the
Collabri model. In both the treatment as usual group and
the CC group, the GPs were subsequently randomised ac-
cording to detection method, which was either standard
detection of depression or case-finding. In standard detec-
tion the GPs were asked to use the MDI [19] as often as
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they usually did. In case-finding the GPs were asked to
systematically use the MDI as a screening tool if they
suspected depression. See Fig. 1 for an illustration of
the randomisation process.
Individual level
Patients within the clusters are allocated to the same
group as their GP. The GPs enrolled in the study detect
patients with depression according to randomisation al-
location. Only patients who meet the criteria for depres-
sion at baseline are included in the depression study.
Patients who have not initially been diagnosed with de-
pression by the GP and have only been referred to the
detection of depression study, and are subsequently di-
agnosed with depression through the Mini International
Neuropsychiatric Interview (MINI), are asked to partici-
pate in the treatment outcome study if the GP agrees
with the diagnosis.
The GP obtains verbal consent from the patient that a
research assistant can make contact by telephone in
order to conduct a diagnostic interview (MINI interview).
If the diagnosis according to the MINI interview is incon-
sistent with the GP’s diagnosis, the research assistant con-
sults a psychiatrist in the Collabri group, who contacts the
GP to confirm which diagnosis is correct. Patient recruit-
ment was initiated in November 2014 and ended on 31
December 2016.
Blinding
It is not possible to ensure blinding of the patient and
GP, but the blinding of GP allocation to intervention
group is maintained for researchers in the data collec-
tion phase and in the analysis phase. The intervention
groups are coded and anonymised (e.g. X and Y) so that
researchers are blinded in the entire phase of the ana-
lysis and when writing the conclusion. In the detection
of depression study, blinding of the patient diagnosis
and the MDI result is maintained for the researchers
during the MINI interview, in order to ensure that the
Fig. 1 Flow-chart for participants
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evaluation of diagnosis is not affected by the GP’s refer-
ral diagnosis.
Care managers, GPs, psychiatrists, and patients are no-
tified that they cannot reveal to the researchers to which
group the patients are allocated. If the blinding is broken
and referral diagnosis, or baseline or outcome measures
are revealed at the baseline interview or at the follow-up
interview, the patient is referred to another blinded
researcher.
The experimental intervention - treatment according to
the Collabri model
Four criteria for CC are listed in the Cochrane review
[9]: a multi-professional approach to treatment, sched-
uled monitoring and review, enhanced inter-professional
communication, and a structured treatment plan. Partic-
ipants in the intervention group are treated according to
the Collabri model, based on the four criteria listed in
the Cochrane review [9] and on the recommendations
from a systematic literature reveiw by Eplov et al. [8],
and adapted to the Danish health care system by includ-
ing collaboration with relevant social worker(s) in the
municipality and integrating the existing psychologist
scheme. On the basis of these and on current guidelines
[1, 22–25], the following elements were integrated into
the Collabri model: recruitment of staff with mental
health care experience, training of GP and care manager,
use of instruments for detection and follow up, educa-
tion and treatment of the patient, supervision from a
psychiatric specialist, and a stepped-care approach to
treatment where treatment is always commenced on the
least invasive and least resource-demanding level. These
elements will be described in detail.
The Collabri model is based on a multi-professional
approach to treatment. Treatment is provided by care
managers, GPs and psychiatrists, all of whom receive a
short training following their recruitment. The care
manager has a medium-long health professional educa-
tion, is often a nurse, and has experience in working in
mental health together with a certified CBT course (of
minimum 1 year). The care manager provides assessment
of side effects due to medical treatment, CBT, supportive
conversations, diagnosis-specific treatment, psychoeduca-
tion and regular contact with social worker(s). The GP has
overall responsibility for treatment and takes care of the
diagnostic procedure, initiation of treatment, coordination
of the treatment intervention with the care manager,
supervision of the care manager, and collaboration with
the care manager on contact with social caseworker(s).
The psychiatrist guides and supervises the care manager
and GP and participates in joint consultations with the
GP.
According to the Collabri model, the patient is regularly
monitored and assessed at scheduled patient follow-up
visits. Monitoring consists of assessments at intervals de-
termined by the severity of depression or anxiety - at least
every 2 weeks, more frequently on signs of significant
change in the condition and at least once per week when
stepping up medication. Review will take place at least
once a month and always at the end of a treatment
component.
The Collabri model includes enhanced inter-professional
communication where the care manager and the GP meet
at minimum weekly and discuss patients. In addition, the
psychiatrist supervises the care managers in groups twice a
month, and the GPs in groups once a month. Furthermore,
the psychiatrist supervises the care managers and GPs
individually when needed.
The psychiatrist, GP, and care manager may have joint
consultations if needed. Communication between pro-
fessionals can take place via video conferences if it is not
possible to meet in person; however, the weekly commu-
nication between the care manager and GP must be face
to face.
The CC treatment for depression and anxiety takes
place according to treatment guidelines established on
the basis of the Danish Health Authority’s reference
programme for unipolar depression in adults [1], The
Danish College of General Practitioners’ guideline for
unipolar depression [22], the Danish Health Authority’s
reference programme for anxiety disorders [24] and The
Danish College of General Practitioners’ clinical guide-
line for anxiety disorders [25].
The Collabri model also focuses on the principles of a
stepped-care approach to treatment, active and planned
follow up, patient involvement and influence on treat-
ment, involvement of carers, and self-management.
The specific treatment modalities in the Collabri
model are medical treatment in accordance with treat-
ment plans in Collabri, psychotherapy in the form of
CBT by a care manager in accordance with treatment
plans in Collabri, psychoeducation in groups in the
form of the course “Lær at takle angst og depression”
(“Learn to cope with anxiety and depression”), based on
the Chronic Disease Management Program (http://
patienteducation.stanford.edu/programs/cdsmp.html)
or individual psychoeducation carried out by the care
manager or psychoeducation as a part of CBT. All pa-
tients and carers are offered written psychoeducational
material.
Fidelity
To ensure the internal validity of the intervention, an
evaluation (fidelity measurement) is carried out after
6 months and at least once more during the project
period. The fidelity measurement ensures that the
intervention is carried out according to the described
Collabri model. Based on the assessments, an action
Brinck-Claussen et al. Trials  (2017) 18:344 Page 5 of 12
plan is developed if needed in order to improve the im-
plementation. The fidelity scale is available through the
corresponding author.
The control intervention - treatment as usual group
GPs in the treatment as usual group treat the participat-
ing patients as they normally do. The treatment is based
on clinical guidelines from The National Board of Health
and The Danish College of General Practice, including
recommendations on detection, diagnosis, treatment,
and referral [23]. The guidelines recommend screening
for depression in risk groups, use of screening tools, e.g.
the World Health Organization (WHO)-5 Well-being
Index (WHO-5) or use of two screening questions, diag-
nosis according to the ICD-10, and treatment according
to a stepped-care model with the following treatment el-
ements: psychotherapy (for mild to moderate depres-
sion) and medical treatment (for moderate depression
not responding to therapy and for severe depression)
(see Fig. 2). The guidelines also recommend, in some
cases, admission to an inpatient ward or referral to or
advice from a psychiatrist, community mental health
centre, or a psychologist.
Assessments and outcome measures
Baseline eligibility interview
The GP assesses referral diagnosis and comorbidity at
recruitment and refers the participant to the study. At
baseline, the participants are interviewed by telephone in
order to assess the inclusion and exclusion criteria and
confirm the diagnosis on the basis of a modified version
of the MINI [26], including ICD-10-specific questions
for the inclusion diagnosis.
Outcome measures in the treatment outcome study
The primary outcome for the treatment outcome study
is self-reported degree of depression measured by the
Beck Depression Inventory (BDI-II) [27] at 6 months.
BDI-II is a 21-item multiple-choice questionnaire asses-
sing degree of depression and changes in depression
mode by measuring symptoms of depression during the
last 14 days. Each item has four statements reflecting in-
crease in symptom severity from scores 0 to 3. The total
score ranges from 0 to 63.
Secondary outcomes for the treatment outcome study
are self-reported degree of depression measured by the
BDI-II [27] at 15 months, self-reported degree of anxiety
measured by the Beck Anxiety Inventory (BAI) [28] at
6 months, functional impairment measured with the
Global Assessment of Functioning (GAF-F, split version)
[29] obtained through a semi-structured interview with
a research assistant, and self-reported psychological stress
measured with the Symptom Checklist (SCL-90-R) [30] at
6 and 15 months.
The BAI is a 21-item multiple-choice questionnaire
assessing physiological anxiety symptoms. Each item has
four statements scoring 0 to 3, reflecting increase in the
degree to which the participant has been bothered with
the symptom over the last week. The total score ranges
from 0 to 63. The GAF-F measures the participants’
level of functioning over the past month on a continu-
ous scale ranging from 0 to 100. The SCL-90-R is a
multi-dimensional questionnaire assessing mental health
problems and psychopathological symptoms on a con-
tinuous scale from the lowest functional level of 0 to the
highest functional level of 100. It consists of 90 items,
each item graded on a scale of 0–4, based on the extent
to which the participant has experienced the symptom
within the past week. The questionnaire measures nine
primary dimensions of symptoms and can be summed in
the global severity index (GSI), measuring overall psy-
chological distress.
Explorative outcomes for the treatment outcome study
are self-reported degree of anxiety measured by the BAI
[28] at 15 months, self-reported quality of life measured
with the WHO-5 [31], psychosocial functioning mea-
sured with the Personal and Social Performance Scale
(PSP) [32], obtained through semi-structured interview
with a research assistant, self-reported side effects mea-
sured by the Patient-Rated Inventory of Side Effects
(PRISE) [33], self-reported health-related quality of life
measured with the EuroQol Five Dimensions Question-
naire with Three Levels (EQ-5D-3 L) [34], self-reported
functional impairment measured with the Sheehan Disabil-
ity Scale (SDS) [35], self-reported self-efficacy measured
with the Illness Perception Questionnaire Revised (IPQ-R)
[36] and two subscale questions from the Chronic Disease
Self-efficacy Scales (SECD-32) [37], self-reported recovery
measured with INSPIRE [38], self-reported general satisfac-
tion with the treatment measured with the Client Satisfac-
tion Questionnaire-8 (CSQ-8) [39], and apathia measured
by a research assistant with the Diagnostic Apathia Scale
Fig. 2 Stepped-care plan
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[40], a 6-item rating scale covering neuropsychological
symptoms. The number of sick leave days, and information
on employment and the use of social services will be ob-
tained from the Danish Register for Evaluation of
Marginalization (DREAM) database [41]. The DREAM
database contains information on all Danish transfer pay-
ments on a weekly basis. Medication use will be obtained
from the Danish National Prescription Registry [42], con-
taining detailed information on prescriptions dispensed in
Denmark. Demographic data will be obtained from Statis-
tics Denmark [43], covering statistics on Danish society,
and the National Prescription Registry [42].
The WHO-5 is a 5-item questionnaire measuring
mental health within the last 2 weeks. Each item is rated
on a Likert scale from 0 (not present) to 5 (constantly
present). The score from 0 to 25 is transformed into a
scale from 0 to 100, where higher scores mean better
well-being. The PSP is a 100-item scale measuring per-
sonal and social functional level within the last month.
The score is based on the assessment of performance
within 4 domains: (1) socially useful activities, (2) per-
sonal and social relationships, (3) self-care, and (4) dis-
turbing and aggressive behaviours. Higher scores mean
better functional level. PRISE is a questionnaire used to
identify and evaluate the tolerability of side effects
within 9 domains. The EQ-5D-3 L measures health sta-
tus within 5 domains: (1) mobility, (2) self-care, (3) usual
activities, (4) pain and discomfort, and (5) anxiety and
depression. The participants self-rate their level of sever-
ity on a 3-level scale and mark their health status on a
visual analogue scale from 0 (worst imaginable health
status) to 100 (best imaginable health status). The SDS
is a self-report tool measuring functional impairment in
3 domains: (1) work and school, (2) social life, and (3)
family life. Symptoms are rated on a visual analogue
scale and can be translated into a single dimensional
measure of global functional impairment, ranging from
0 (unimpaired) to 30 (highly impaired). The subscales
from the SECD-32 measure self-efficacy. The partici-
pants rate how confident they are in doing certain activ-
ities. Each item is rated on a 10-point Likert scale from
1 (not at all confident) to 10 (very confident). The IN-
SPIRE questionnaire assesses the participant’s feeling of
being supported in their recovery by their health care
provider (the GP and possibly the care manager). The
first 20-item part covers support from the therapist and
the second 7-item part covers the relationship with the
therapist. The IPQ-R subscale on personal control mea-
sures confidence in one’s own ability to influence dis-
ease. Each of the 6 items is self-rated on a 5-point Likert
scale from 1 (very disagree) to 5 (strongly agree). The
CSQ-8 is an 8-item questionnaire that measures general
satisfaction with the treatment. Each item is rated on a
scale from 0 to 4.
At baseline the following will also be registered:
somatic comorbidity reported by the GP at the point
of referral, and personality disorder measured by the
Standardized Assessment of Personality: Abbreviated
Scale (SAPAS) [44], an 8-item screening interview.
Safety measures
Self-reported anxiety and depression symptoms are mea-
sured by the BAI and BDI-II. Suicidal ideation is evalu-
ated in the MINI interview. Data on death are obtained
from the Danish Cause of Death Register [45]. The num-
ber of outpatient services, admissions, inpatient days,
and life-threatening conditions for reasons other than
suicide attempts are obtained from the Danish National
Patient Registry (Landspatientregistret) [3] containing
data on Danish patients’ contacts with hospitals in
Denmark. Numbers of sick leave days are obtained from
the DREAM database.
Outcome measures in the detection of depression study
The primary outcome for the detection of depression
study is the positive predictive value of referral diagnosis
in two randomised detection settings: case-finding and
standard detection. In the standard detection group, based
on results from the referral diagnosis performed by the
GP and the MINI carried out by the research assistant,
the positive predictive value of the GP’s diagnosis is calcu-
lated. In the case-finding group, based on results from the
MDI and MINI, the positive predictive value of the diag-
nosis and the sensitivity, specificit, and negative predictive
value of the diagnosis are calculated.
Data collection
The data for the outcome study will consist of interviewer-
based data (telephone interview), register data, and self-
reported data. Participants will be interviewed by telephone
at baseline, and again after 6 and 15 months in order to
collect data for GAF and PSP. SAPAS is collected at the
baseline interview. Data collection through interviews
will be conducted by staff trained in the specific instru-
ments. The participants also complete self-assessment
questionnaires at baseline, and again after 6 and 15 months.
Self-assessments will be completed electronically, but a
paper version can be posted if preferred. If one or more
items in the questionnaire have not been answered, the
patient will be contacted by the research assistant in
order to complete the questionnaire and to clear any
doubts the patient may have. Services in relation to the
Collabri intervention will be registered by the care
managers and psychiatrists. See Table 1 for schedule of
enrolment, interventions and assessments.
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Training and inter-rater reliability
All assessors have received the necessary training in the
relevant instruments and receive ongoing support and
supervision. All assessors have participated in regular
joint ratings for PSP and GAF, in order to ensure inter-
rater reliability. All cases of discrepancy between the re-
ferral diagnosis and a diagnosis made at the inclusion
interview via the MINI interview will be discussed with
the psychiatrist and the referring GP.
Power and sample size
We made two sample size calculations, one for the depres-
sion treatment outcome study and one for the detection of
depression study to see how many people to include in the
Table 1 Schedule of enrolment, interventions and assessments
Study period
Recruitment Baseline Post-baseline Source of data collection
Timepoint Treatment
period
Follow up,
6 months
Follow up,
15 months
Enrolment Referral diagnosis, information and
informed consent
x GP
Assessment of somatic comorbidity x GP
Eligibility interview (including MINI) x Interview
Standardized Assessment of Personality,
Abbreviated Scale
x Interview
Suicidal ideation x Interview
Interventions Collaborative care x
Treatment as usual x
Assessments Beck Depression Inventory-II x x x Self-report
Beck Anxiety Inventory x x x Self-report
Global Assessment of Functioning x x x Self-report
Symptom Checklist-90-Revised x x x Interview
World Health Organization-5 x x x Self-report
Personal and Social Performance Scale x x x Interview
Patient-Rated Inventory of Side Effects x x x Self-report
EuroQol Five-Dimension Questionnaire
with Three Levels
x x x Self-report
Sheehan Disability Scale x x x Self-report
Subscale from Illness Perception
Questionnaire Revised scale
x x x Self-report
Chronic Disease Self-efficacy Scales-32 x x x Self-report
INSPIRE x Self-report
Client Satisfaction Questionnaire-8 +
project-specific questions
x Self-report
The Diagnostic Apathia Scale x x x Interview
Sick leave x x x Register
Medication use x x x Register
Death x x x Register
Life-threatening conditions x x x Register
Outpatient services, admissions and
inpatient days
x x x Register
Use of social services x x x Register
Intervention-specific services and treatment x Care managers and
psychiatrists
MINI Mini International Neuropsychiatric Interview
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depression treatment outcome study with the embedded
detection of depression study
Sample-size calculation for the depression treatment
outcome study
The primary outcome is a change in the BDI-II summary
score. Clinical relevant treatment response at group level
is defined as a difference in the degree of depression by 4
points measured by the BDI-II [46, 47]. No surveys have
been carried out in Denmark that can contribute to the
estimation of the standard deviation (SD) for BDI-II.
However, according to international surveys, the SD for
BDI-II can be set at 11 [46, 48–50]. There is no knowledge
of the size of the intra-class correlation (ICC) in a Danish
context; however a review of ICCs in depression in pri-
mary care suggests that the ICC can be set at 0.04 [51].
The sample-size calculation for the depression study
based on the aforementioned figures shows that 328 par-
ticipants with depression should be included in order to
be able to reject the null hypothesis in the depression
study. According to the null hypothesis, participants in
the intervention group and the control group improve
similarly in terms of symptoms with a power of 0.8 and
a significance level of 0.05.
Sample size calculation for the detection of depression study
On the basis of a study carried out by Michell et al. [13],
the positive predictive value of standard detection is esti-
mated to be 45%. A clinical meaningful and possible [52]
increase in the number is estimated to be up to detection
of 60%. With the detection of depression study embedded
in the depression study, the sample size calculation shows
that 480 individuals should be included in order to be able
to reject the null hypothesis in the depression study. Ac-
cording to the null hypothesis, participants in the inter-
vention group and the control group improve similarly in
terms of symptoms, with a power of 0.8 and a significance
level of 0.05.
Summary
In all, 480 individuals should be included in the Collabri
treatment for depression outcome study with the em-
bedded detection of depression study in order to reject
the null hypothesis.
Secondary outcomes
The power for the secondary outcomes for depression is
estimated to be over 0.8 for all analyses [53–55]. See
Table 2.
Feasibility
By including 48 GPs, the GPs must each include 10-11
people with depression in the depression treatment out-
come study with the embedded detection of depression
study over a 15-month period. This is possible as
12 months prevalence rates indicate that a GP with 1600
registered patients on average will see 140 patients with
depression per year [2].
Eight full-time care managers and one and a half psy-
chiatrists (one full-time and one part-time) are employed
in the Collabri project. Each care manager has a maximum
caseload of 100 participants per year. Thus, it is realistic in
terms of the capacity of care managers to complete the
intervention in 240 participants with depression.
Statistical analysis
The Collabri study will be conducted according to the
statistical principle “intention-to-treat” [56], which means
that once a person is included in the project, he or she
stays in the study population and is followed, regardless of
whether the person is later excluded. In the detection of
depression study the positive predictive value will be cal-
culated and compared for both groups. Subgroup analysis
will be performed in patients with a medical comorbidity
and a personality disorder.
Linear mixed-effects regression models will be used to
compensate for the cluster randomisation and potential
confounders. To account for repeated measures, multi-
level regression models with random effects will be used,
estimated using an unstructured covariance matrix if
possible. If not possible, other covariance matrices such
as independent, interchangeable, auto-regressive, and
Toeplitz will be estimated, and the best-fitting structure
selected based on Bayes’ information criterion. This
makes it possible to take “missing at follow up” into ac-
count under the assumption of “missing at random” by
including covariates that are associated with missing
values at follow up. The analysis levels are by GP, pa-
tients, and time. This method introduces less bias than
the method whereby the last observation is used instead
of the missing values, and the method whereby only
Table 2 Power calculation for the secondary outcomes
Secondary outcome Mean difference (MD) Standard deviation (SD) of the pooled mean Type 1 error Calculated power
BAI 4 (57) 12 (57) 5% 99%
GAF-F 5 (*) 10 (56) 5% 99%
SCL-90-R 23 (55) 50 (55) 5% 99%
Abbreviations: MD mean difference, SD standard deviation, BAI Beck Anxiety Inventory, GAF-F Global Assessment of Functioning, SCL-90-R Symptom Checklist-90-
Revised. *The expected mean difference for GAF-F has been conservatively estimated to 5 points as this is considered clinically relevant
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cases with complete follow-up information are eligible
for the analysis.
Project organisation
The project is led by a steering group. The aim of the
steering group is to ensure the progress of the research
project. A lead project manager ensures the general
management of the project together with a project man-
ager in charge of implementation of the intervention
and a project manager in charge of the research project.
Administrative staff support the project managers. Data
collection and analysis are carried out by Ph.D. students
and research assistants.
Discussion
The Collabri model is based on the evidence supporting
CC in other countries. To our knowledge this is the first
randomised trial investigating the effect of a CC model
for depression in a Scandinavian context. The strength
of the outcome study is the centralised computer-based
cluster randomization, which ensures adequate generation
of the allocation sequence and adequate allocation con-
cealment. The use of blinded outcome assessors for the
secondary outcome, the fact that it is a register-based out-
come, and the use of intention-to-treat analysis decreases
the risk of biased effect estimates. The strength of the
detection of depression study is also the centralised
computer-based cluster randomisation and the use of
blinded assessors of the outcomes. The trial is registered
at http://www.clinicaltrials.gov, which helps prevent se-
lective and incomplete outcome reporting. The fact that
we monitor fidelity to the Collabri model after 6 months
is also a strength of the trial. This is intended to ensure
that care managers, psychiatrists, and GPs are true to the
model. A limitation of this trial is that we are not able to
blind participants, care managers, psychiatrists, or GPs to
the allocation. Another limitation is that the primary out-
come is self-reported and therefore not blinded, which
may well lead to overestimation of treatment effects. Some
might argue that it is difficult to sustain the blinding of
the assessor during follow up, and this certainly leads to
risk of bias. Should blinding be broken, a second assessor
will complete the follow-up interview.
Although participants are recruited from general prac-
tices throughout the Capital Region of Denmark, and
should be fairly representative of the population in the
region, there may be reduced external validity. As it is
the GP who identifies eligible participants, not every-
body with depression who is eligible may be asked to
participate, as patients are not systematically screened
for eligibility. Due to differences in healthcare systems,
the results may not be directly comparable with other
countries, but together with other trials in the area, it
will give a more complete picture of the effects of collab-
orative care in people with depression.
The results of this trial will add to the knowledge of col-
laborative care for depression in a Scandinavian context. If
the Collabri model is shown to be more effective than treat-
ment as usual in general practice, the results can contribute
to improving the care and treatment for patients with de-
pression in general practice with benefits to both patients
and society. The results of the detection of depression study
add to the knowledge of detection of depression in primary
care. If case-finding is shown to be superior to standard de-
tection, it will be recommended as a detection method in
future treatment according to the Collabri model.
Trial status
Recruitment of participants within the clusters is ongoing
and continued until the 31 December 2016.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOC 124 kb)
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